{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:44:39Z","timestamp":1794426279502,"version":"4.9.1"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160148"],"award-info":[{"award-number":["82160148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["23JRRA1509"],"award-info":[{"award-number":["23JRRA1509"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2023RCXM42"],"award-info":[{"award-number":["2023RCXM42"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["CY2024-LC-A01"],"award-info":[{"award-number":["CY2024-LC-A01"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2023-ct06"],"award-info":[{"award-number":["lzujbky-2023-ct06"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["24ZDFA007"],"award-info":[{"award-number":["24ZDFA007"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105208","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:21:30Z","timestamp":1771028490000},"page":"105208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions"],"prefix":"10.1016","volume":"221","author":[{"given":"Zhongze","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchen","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-8164","authenticated-orcid":false,"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.critrevonc.2026.105208_bib1","doi-asserted-by":"crossref","first-page":"12659","DOI":"10.3390\/ijms232012659","article-title":"Her-2 targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates","volume":"23","author":"Albarr\u00e1n","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105208_bib3","article-title":"Combining radiotherapy and NK cell-based therapies: the time has come","volume":"378","author":"Anon","year":"2023"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105208_bib4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ni.3838","article-title":"Srebp-controlled glucose metabolism is essential for NK cell functional responses","volume":"18","author":"Assmann","year":"2017","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105208_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11864-025-01317-5","article-title":"PSMA-based therapies and novel therapies in advanced prostate cancer: the now and the future","volume":"26","author":"Ayzman","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105208_bib6","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1073\/pnas.96.7.3957","article-title":"Evidence for a structural motif in Toxins and Interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome","volume":"96","author":"Baluna","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105208_bib7","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"issue":"10297","key":"10.1016\/j.critrevonc.2026.105208_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-Cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105208_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ucl.2020.07.002","article-title":"Harnessing natural killer cell function for genitourinary cancers","volume":"47","author":"Bhardwaj","year":"2020","journal-title":"Urol. Clin. North Am."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105208_bib10","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1158\/1078-0432.CCR-21-0971","article-title":"FLT3L release by natural killer cells enhances response to radioimmunotherapy in preclinical models of HNSCC","volume":"27","author":"Bickett","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105208_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105208_bib12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105208_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12885-022-09259-z","article-title":"Nectin-4 and DNA Mismatch Repair Proteins Expression in Upper Urinary Tract Urothelial Carcinoma (UTUC) as a Model for Tumor Targeting Approaches: An ImGO Pilot Study","volume":"22","author":"Calandrella","year":"2022","journal-title":"BMC Cancer"},{"issue":"7714","key":"10.1016\/j.critrevonc.2026.105208_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105208_bib16","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.3390\/cancers13102500","article-title":"Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs","volume":"13","author":"Capuano","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105208_bib17","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2013drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib18","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non\u2013muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid."},{"issue":"October","key":"10.1016\/j.critrevonc.2026.105208_bib19","article-title":"Immune suppression in MTAP-deficient cancers via glutamate metabolism and CXCL10 downregulation","volume":"16","author":"Chang","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105208_bib20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.medj.2021.06.002","article-title":"Getting better mileage with logically primed CARs","volume":"2","author":"Chen","year":"2021","journal-title":"Med"},{"issue":"June","key":"10.1016\/j.critrevonc.2026.105208_bib21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3389\/fonc.2020.00874","article-title":"Immunomodulation of NK cells by ionizing radiation","volume":"10","author":"Chen","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2175517","article-title":"CD25bright NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression","volume":"12","author":"Chen","year":"2023","journal-title":"OncoImmunology"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105208_bib23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"591","key":"10.1016\/j.critrevonc.2026.105208_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"568","key":"10.1016\/j.critrevonc.2026.105208_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti\u2013PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105208_bib26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"issue":"March","key":"10.1016\/j.critrevonc.2026.105208_bib27","article-title":"Cancer immune evasion through loss of MHC Class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"issue":"May","key":"10.1016\/j.critrevonc.2026.105208_bib28","article-title":"CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy","volume":"16","author":"Dos Reis","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-019-0956-8","article-title":"Natural killer group 2D receptor and its ligands in cancer immune escape","volume":"18","author":"Duan","year":"2019","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105208_bib30","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/s41423-020-0365-3","article-title":"Enforced PGC-1\u03b1 expression promotes CD8 T cell fitness, memory formation and antitumor immunity","volume":"18","author":"Dumauthioz","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose Interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"December","key":"10.1016\/j.critrevonc.2026.105208_bib32","article-title":"The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma","volume":"67","author":"Estephan","year":"2023","journal-title":"Ann. Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40425-018-0445-4","article-title":"Immunotherapy utilizing the combination of natural killer\u2013 and antibody dependent cellular cytotoxicity (ADCC)\u2013mediating agents with Poly (ADP-Ribose) Polymerase (PARP) inhibition","volume":"6","author":"Fenerty","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12916-016-0715-2","article-title":"Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells","volume":"14","author":"Ferreira-Teixeira","year":"2016","journal-title":"BMC Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105208_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101454","article-title":"Conditional deletion of PGC-1\u03b1 results in energetic and functional defects in NK cells","volume":"23","author":"Gerbec","year":"2020","journal-title":"iScience"},{"issue":"10473","key":"10.1016\/j.critrevonc.2026.105208_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105208_bib37","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107848","article-title":"Metabolic modulation of immunity: a new concept in cancer immunotherapy","volume":"32","author":"Guerra","year":"2020","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105208_bib40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"591","key":"10.1016\/j.critrevonc.2026.105208_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105208_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121788","article-title":"Identification of an ADAM17 cleavage region in human CD16 (Fc\u03b3RIII) and the engineering of a non-cleavable version of the receptor in NK cells","volume":"10","author":"Jing","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13287-022-02769-4","article-title":"Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer","volume":"13","author":"Kennedy","year":"2022","journal-title":"Stem Cell Res. Ther."},{"issue":"January","key":"10.1016\/j.critrevonc.2026.105208_bib45","article-title":"Transcriptional signature of CD56bright NK cells predicts favourable prognosis in bladder cancer","volume":"15","author":"Khan","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105208_bib46","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/biom15070935","article-title":"Overcoming immune barriers in allogeneic CAR-NK therapy: from multiplex gene editing to AI-driven precision design","volume":"15","author":"Kim","year":"2025","journal-title":"Biomolecules"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105208_bib47","doi-asserted-by":"crossref","first-page":"16130","DOI":"10.18632\/oncotarget.7470","article-title":"IL-15 Superagonist\/IL-15R\u03b1Sushi-Fc fusion complex (IL-15SA\/IL-15R\u03b1Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib48","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4111\/icu.20250316","article-title":"Treatment strategies for cisplatin-ineligible metastatic bladder cancer: emerging therapies and future perspectives","volume":"66","author":"Kim","year":"2025","journal-title":"Invest. Clin. Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105208_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078049","article-title":"Reduction of the CD16\u2212CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer","volume":"8","author":"Koo","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105208_bib50","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3390\/cancers16132420","article-title":"Antibody-drug conjugates in urothelial cancer: from scientific rationale to clinical development","volume":"16","author":"Kwon","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing cancer immunotherapies that engage T cells and NK cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105208_bib52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105208_bib53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105208_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294857","article-title":"Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing","volume":"19","author":"Lee","year":"2024","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib55","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-\u03921","volume":"182","author":"Li","year":"2009","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105208_bib56","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/biom14081035","article-title":"CAR-NK cell therapy: a transformative approach to overcoming oncological challenges","volume":"14","author":"Li","year":"2024","journal-title":"Biomolecules"},{"issue":"February","key":"10.1016\/j.critrevonc.2026.105208_bib57","article-title":"NK cells in renal cell carcinoma and its implications for CAR-NK therapy","volume":"13","author":"Li","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12967-025-06291-y","article-title":"New insights on anti-tumor immunity of CD8+ T cells: cancer stem cells, tumor immune microenvironment and immunotherapy","volume":"23","author":"Lin","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib61","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1038\/s41467-018-04719-2","article-title":"Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice","volume":"9","author":"Loftus","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib63","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/cancers11060769","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","volume":"11","author":"Lupo","year":"2019","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105208_bib64","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jimmun\/vkaf036","article-title":"Natural killer cell\u2013based immunotherapy for cancer","volume":"214","author":"Ma","year":"2025","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib65","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105208_bib66","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7897","key":"10.1016\/j.critrevonc.2026.105208_bib67","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105208_bib68","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/bloodadvances.2021006440","article-title":"Interleukin-15 augments NK cell\u2013mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies","volume":"7","author":"Miljkovic","year":"2023","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105208_bib69","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib70","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/cells9061382","article-title":"Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer","volume":"9","author":"Montagner","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105208_bib71","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"issue":"92","key":"10.1016\/j.critrevonc.2026.105208_bib72","doi-asserted-by":"crossref","first-page":"36492","DOI":"10.18632\/oncotarget.26362","article-title":"Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer","volume":"9","author":"Mukherjee","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105208_bib73","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105208_bib74","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib75","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350878","article-title":"Tumor-associated macrophages impair NK cell IFN-\u03b3 production and contribute to tumor progression in clear cell renal cell carcinoma","volume":"54","author":"N\u00fa\u00f1ez","year":"2024","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105208_bib77","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/ijc.32269","article-title":"Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and Inhibit in vivo leukemia growth","volume":"145","author":"Oelsner","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105208_bib78","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105208_bib79","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105208_bib80","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105208_bib81","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2326-6066.CIR-24-0273","article-title":"A PSMA-targeted tri-specific killer engager enhances NK cell cytotoxicity against prostate cancer","volume":"13","author":"Phung","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"April","key":"10.1016\/j.critrevonc.2026.105208_bib82","article-title":"A systematic review of Interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"eBioMedicine"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105208_bib83","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.smim.2006.03.003","article-title":"Missing self recognition and self tolerance of natural killer (NK) cells","volume":"18","author":"Raulet","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105208_bib84","article-title":"Nectin-4 in bladder cancer: biology and predictive biomarker potential","author":"Roessler","year":"2025","journal-title":"Curr. Opin. Urol."},{"issue":"July","key":"10.1016\/j.critrevonc.2026.105208_bib85","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front. Immunol."},{"issue":"March","key":"10.1016\/j.critrevonc.2026.105208_bib86","article-title":"Taking lessons from CAR-T cells and going beyond: tailoring design and signaling for CAR-NK cells in cancer therapy","volume":"13","author":"Ruppel","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105208_bib87","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib88","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac003","article-title":"Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy","volume":"2","author":"Schmidt","year":"2022","journal-title":"Immunother. Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","article-title":"Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures","volume":"17","author":"\u015eenbabao\u011flu","year":"2016","journal-title":"Genome Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105208_bib90","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105208_bib91","doi-asserted-by":"crossref","DOI":"10.1101\/2025.01.21.632253","article-title":"B7-H3 as a dual clinically relevant checkpoint and antibody drug conjugate target expressed across adenocarcinoma and neuroendocrine prostate cancers","author":"Sharma","year":"2025","journal-title":"Prepr. Cancer Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40164-024-00561-z","article-title":"Natural killer cell-based cancer immunotherapy: from basics to clinical trials","volume":"13","author":"Shi","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105208_bib93","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.smim.2014.02.007","article-title":"NK cell self tolerance, responsiveness and missing self recognition","volume":"26","author":"Shifrin","year":"2014","journal-title":"Semin. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105208_bib94","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib95","first-page":"12","article-title":"Cancer Statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib96","first-page":"10","article-title":"Cancer Statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"July","key":"10.1016\/j.critrevonc.2026.105208_bib97","article-title":"Myeloid-derived suppressor cells as key players and promising therapy targets in prostate cancer","volume":"12","author":"Siemi\u0144ska","year":"2022","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105208_bib98","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/14712598.2016.1195364","article-title":"Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer","volume":"16","author":"Smits","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105208_bib99","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-21-1052","article-title":"TGF\u03b2 and CIS inhibition overcomes NK-cell suppression to restore antitumor immunity","volume":"10","author":"Souza-Fonseca-Guimaraes","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105208_bib100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"March","key":"10.1016\/j.critrevonc.2026.105208_bib101","article-title":"Innovative strategies to improve the clinical application of NK cell-based immunotherapy","volume":"13","author":"Tarannum","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105208_bib102","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","article-title":"NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer","volume":"14","author":"Taylor","year":"2024","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105208_bib103","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-shelf prostate stem cell antigen\u2013directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"issue":"May","key":"10.1016\/j.critrevonc.2026.105208_bib104","article-title":"Cytokine-induced memory-like NK cells: from the basics to clinical applications","volume":"13","author":"Terr\u00e9n","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib105","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105208_bib106","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/sji.12524","article-title":"Immune regulation by T regulatory cells in hepatitis B virus-related inflammation and cancer","volume":"85","author":"Trehanpati","year":"2017","journal-title":"Scand. J. Immunol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105208_bib107","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105208_bib108","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jcyt.2025.08.001","article-title":"PSCA-CAR-NK cells exert cytotoxic activity against PSCA-expressing tumor cells and are characterized by a specific chemokine profile","volume":"27","author":"Velichinskii","year":"2025","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105208_bib109","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105208_bib110","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/curroncol29030117","article-title":"Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies","volume":"29","author":"Voutsadakis","year":"2022","journal-title":"Curr. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105208_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh4050","article-title":"Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8","volume":"8","author":"Walle","year":"2022","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib112","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/biom15060826","article-title":"Role of tumor microenvironment in prostate cancer immunometabolism","volume":"15","author":"Wang","year":"2025","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105208_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009560","article-title":"Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib115","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/JLB.2MR1218-501R","article-title":"Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy","volume":"105","author":"Wu","year":"2019","journal-title":"J. Leukoc. Biol."},{"issue":"September","key":"10.1016\/j.critrevonc.2026.105208_bib116","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"eBioMedicine"},{"issue":"July","key":"10.1016\/j.critrevonc.2026.105208_bib117","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3389\/fimmu.2020.01324","article-title":"Molecular mechanism of tumor cell immune escape mediated by CD24\/Siglec-10","volume":"11","author":"Yin","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib118","article-title":"Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells","volume":"32","author":"Yoon","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105208_bib119","first-page":"275","article-title":"CAR NK cell therapy for solid tumors: potential and challenges","volume":"8","author":"Yu","year":"2025","journal-title":"Antib. Ther."},{"key":"10.1016\/j.critrevonc.2026.105208_bib120","first-page":"1","article-title":"Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma","volume":"2017","author":"Zhang","year":"2017","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105208_bib121","article-title":"Bortezomib improves adoptive carbonic anhydrase\u2370IX\u2011specific chimeric antigen receptor\u2011modified NK92 cell therapy in mouse models of human renal cell carcinoma","author":"Zhang","year":"2018","journal-title":"Oncol. Rep."},{"issue":"October","key":"10.1016\/j.critrevonc.2026.105208_bib122","article-title":"Breaking immune evasion in breast cancer by targeting COX-2\/PGE2 pathway","volume":"608","author":"Zheng","year":"2025","journal-title":"Mol. Cell. Endocrinol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105208_bib123","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell\u2013derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"issue":"June","key":"10.1016\/j.critrevonc.2026.105208_bib124","article-title":"Metabolic reprogramming of clear cell renal cell carcinoma","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105208_bib125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13046-025-03273-2","article-title":"LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells","volume":"44","author":"Zhu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:18:13Z","timestamp":1777605493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":125,"alternative-id":["S1040842826000958"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105208","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105208"}}